Investors in Life Science

SOSV is venture capital firm and an accelerator specializing in technology startups. The firm also specializes in seed, early venture, growth capital, venture and growth-stage funding to disruptive startups. The firm typically invests in information technology with a focus on hardware, software, leap motion, sales and biotechnology, telecommunications, energy efficiency technology, energy, green energy, medical devices, transportation, robotics, internet, and social media; it also invests in the food sector. It seeks to invest globally with a focus on United States, Europe, and Asia including China. The firm typically invests between $0.01 million and $0.05 million and offers a two-four month program in exchange for equity. The firm prefers to invest as the lead investor. SOSV was founded in 1995 and is based in Princeton, New Jearsey with additional offices in United States of America, Europe, and Asia.

The Morningside Group Limited is a private equity and venture capital firm specializing in early stage. It seeks to make investments in machinery manufacturing, high-tech, life science companies formed around new technologies, media, the Internet, biotechnology, telecommunication, life science, entertainment, consumer, education, and clean tech sectors. It seeks to invest in companies based in North America, Europe, and Asia Pacific, where its particular focus is on China. The Morningside Group Limited was founded in 1986 and is based Hong Kong with additional offices in Shanghai, China; Beijing, China; and Boston, United States.

We’re (not just) investors. We’re (more than) advisors. We’re (beyond) connectors. Ben Franklin Technology Partners combines the best practices of early stage investing with a higher purpose – to lead the region’s technology community to new heights, creating jobs and transforming lives. For over 30 years, Ben has been the leading seed stage capital provider for the region’s technology sectors, investing over $170 million in more than 1,750 regional technology companies, many of which have gone on to become industry leaders. Ben Franklin has also launched university/industry partnerships that accelerate scientific discoveries to commercialization, and has seeded regional initiatives that strengthen our entrepreneurial community.

Arch Venture Partners, L.P. is a private equity and venture capital firm specializing in investments in growth capital and development of seed and early-stage technology companies. It invests conservatively at first in a seed round to reduce or extinguish risk and then leads or co-leads additional rounds of financing all the way to liquidity. It seeks to invest in disruptive technologies worldwide. It primarily invests with focus on life sciences, biotechnology, chemicals and specialty materials, advanced materials, specialty semiconductors, consumer electronics, instrumentation, physical sciences, communications technologies, electronics, software/applications, Nanotechnology, alternative energy, retailing, e-commerce software, b2b commerce, enterprise information portals, knowledge management software , convergence technology, and information technology. Within technology, it invests in clean technology innovations, optics and photonics, electronic components, network infrastructure and security, high performance computing, wireless communications, pharmaceuticals, genomics and bioinformatics, medical devices, diagnostic and drug discovery platforms; nano- and microtechnologies. It maintains its presence in geographical areas that are typically underserved by seed investors but contain great centers of basic research and an active community of technologists. It maintains a national scope with a regional focus in geographic markets underserved by venture community. Within the healthcare sector, the fund focuses on companies working on neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis and also invests in companies addressing mental health needs around cognition, depression, schizophrenia and autism. It invests primarily in the United States but also in countries where the company has extensive scientific and business relationships, including Canada, Ireland, Iceland, South Korea, China, and Japan. It also seeks to invest in Europe. The firm typically invests between $50,000 and $150 million per company. The firm seeks a seat on the Board of Directors. Arch Venture Partners, L.P. was founded in 1986 and is based in Chicago, Illinois with additional offices across North America and South America.

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S. and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.

Casdin Capital, LLC is an investment firm focused on the life sciences and healthcare industry.

ArchiMed SAS is a private equity firm specializing investing in buyouts and growth capital of small to mid cap companies and lower mid-market. The firm seeks to invest in small and medium-sized companies in the healthcare sector with a focus on care and wellness including homecare, wellness centers, telemedicine, and hospital outsourcing services; medtech including medical devices and disposables, implants, diagnostics, healthcare information technology, life science tools, hygiene products, and medtech distributors; biopharma including specialty bioPharma companies, active pharmaceutical ingredients producers, contract manufacturing, animal health, contract research organizations, medical affairs, OTC products and wellness product manufacturers; and public health including health at work, food safety, environmental security, forensic. It prefers to invest in Europe with a focus on Western Europe including France, the United Kingdom, and Switzerland. The firm typically invests between €5 million ($6.22 million) and €15 million ($18.65 million) per transaction but the full range for the firm is between €2 million ($2.49 million) to €50 million ($59.7 million) or higher, alone or with co-investors. It invests in companies with revenues between €5 million ($6.22 million) and €100 million ($124.33 million), but with the ability to go beyond. The firm takes both minority and majority stakes, mostly in unlisted companies. ArchiMed SAS was founded in 2014 and is based in Lyon, France with an additional office in Paris, France.

Wellington Management Company is a Boston based institutional investment advisor firm. The firm invests in global equity, fixed income, currency and commodity markets, multi-strategy, specialty and alternative investments. The firm offers separate accounts and a wide range of commingled vehicles that include both US and non-US domiciled portfolios. The company was founded in 1928.

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

Full Investment Portfolio Liquid and sub-20% listed asset 36% Liquid large blocs (between 20% and 50% share) 10% Listed large blocs (over 50% share) 12% Unlisted assets 42% Founded in 1974 to hold Singapore government investments in various businesses, Temasek is an active shareholder in a broad range of industries, ranging from transportation and logistics, to finance, telecommunications, engineering and property. Its portfolio comprises cash, fixed income, equities, absolute returns strategies and private equity funds.